Baseline characteristics
| Characteristic . | % (n) (N = 311) . |
|---|---|
| Age | |
| <1 y old | 7 (22) |
| >1 to <10 y old | 69 (215) |
| ≥10 y old | 24 (74) |
| Sex | |
| Male | 63 (195) |
| Female | 37 (116) |
| Initial white blood cell count | |
| <50 000/mm3 | 68 (214) |
| 50 000 to <100 000/mm3 | 10 (30) |
| ≥100 000/mm3 | 22 (67) |
| Initial platelet count | |
| <20 000 | 33 (101) |
| 20 000-99 000 | 48 (150) |
| ≥100 000 | 18 (57) |
| CNS involvement at diagnosis | 1.6 (5) |
| Immunophenotype | |
| B-cell ALL | 73% (228) |
| T-cell ALL | 18% (57) |
| Mixed phenotype | 0.6% (2) |
| Unknown | 8% (24) |
| Risk group stratification | |
| SR | 47 (145) |
| HR | 53 (166) |
| Characteristic . | % (n) (N = 311) . |
|---|---|
| Age | |
| <1 y old | 7 (22) |
| >1 to <10 y old | 69 (215) |
| ≥10 y old | 24 (74) |
| Sex | |
| Male | 63 (195) |
| Female | 37 (116) |
| Initial white blood cell count | |
| <50 000/mm3 | 68 (214) |
| 50 000 to <100 000/mm3 | 10 (30) |
| ≥100 000/mm3 | 22 (67) |
| Initial platelet count | |
| <20 000 | 33 (101) |
| 20 000-99 000 | 48 (150) |
| ≥100 000 | 18 (57) |
| CNS involvement at diagnosis | 1.6 (5) |
| Immunophenotype | |
| B-cell ALL | 73% (228) |
| T-cell ALL | 18% (57) |
| Mixed phenotype | 0.6% (2) |
| Unknown | 8% (24) |
| Risk group stratification | |
| SR | 47 (145) |
| HR | 53 (166) |